Heron Therapeutics, Inc. (HRTX)

Market Cap	240.31M
Revenue (ttm)	137.74M
Net Income (ttm)	-27.97M
Shares Out	152.09M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,431,738
Open	1.480
Previous Close	1.530
Day's Range	1.460 - 1.620
52-Week Range	1.040 - 3.930
Beta	1.69
Analysts	Strong Buy
Price Target	5.67 (+258.86%)
Earnings Date	Nov 12, 2024

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 126
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX
• Website: https://www.herontx.com

Financial Performance

In 2023, Heron Therapeutics's revenue was $127.04 million, an increase of 17.99% compared to the previous year's $107.67 million. Losses were -$110.56 million, -39.26% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 258.86% from the latest price.

Price Target

$5.67

(258.86% upside)

Analyst Consensus: Strong Buy